Home Categories API Pasireotide
M5037935

Pasireotide , 98% , 396091-73-9

CAS NO.:396091-73-9

Empirical Formula: C58H66N10O9

Molecular Weight: 1047.23

MDL number: MFCD08067735

Pack Size Price Stock Quantity
1mg RMB2276.00 In Stock
5mg RMB9408.00 In Stock
others     Enquire
Update time: 2022-07-08

PRODUCT Properties

Boiling point: 1351.4±65.0 °C(Predicted)
Density  1.36±0.1 g/cm3(Predicted)
storage temp.  Store at -20°C
solubility  Soluble in DMSO
form  Powder
pka 11.86±0.46(Predicted)
Sequence cyclo[Tyr(Bzl)-Phe-Hyp(Bom)-Phg-D-Trp-Lys]

Description and Uses

In April 2012, the European Commission approved pasireotide for the treatment of Cushing’s Disease (CD) in adult patients who have not responded to surgical interventionor forwhomsurgery is not anoption.Pasireotide was approved for the same indication by the US FDA in December of 2012. Pasireotide (also known as SOM230) is a cyclohexapeptide that acts as a somatostatin analogue to inhibit the release of ACTH. Somatostatins are cyclic peptides of 14 and 28 amino acids that play animportant role inregulating endocrineandexocrine release inmany tissues through an inhibitory mechanism. There are five known subtypes of somatostatin receptors (SSTRs). Natural somatostatins bind with high affinity to all five subtypes, however, their therapeutic use is limited by rapid degradation in plasma. Pasireotide arose fromefforts to identify a somatostatinmimetic with long-lasting inhibitory effects. Starting with a 14-amino acid somatostatin peptide, a systematic alanine scan revealed residues that were essential for receptor sub-type binding, including key b-turn regions and adjacent residues. Placing the key structural elements as unnatural amino acids in a cyclohexapeptide backbone gave pasireotide.

Pasireotide can be used in biological study of long-term treatment of Cushing''s disease with pasireotide, 5-yr results from open-label extension study of Phase III trial.

Safety

RELATED PRODUCTS